טוען...
Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
INTRODUCTION: Treatment for metastatic colorectal cancer (mCRC), employing various schedules, combinations, and regimens utilizing 5-fluorouracil (5-FU), irinotecan, oxaliplatin, capecitabine, bevacizumab, and cetuximab, currently achieves an overall survival that extends to approximately two years....
שמור ב:
מחבר ראשי: | |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Dove Medical Press
2009
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108637/ https://ncbi.nlm.nih.gov/pubmed/21694822 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|